Pieris' Artificial Protein Platform Is Undervalued By The Street, Analyst Says

By: via Benzinga
Shares of the clinical-stage biotech companyPieris Pharmaceuticals Inc (NASDAQ: PIRS) are poised to outperform over the coming 12 ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.